Third generation dendritic cell vaccines for tumor immunotherapy
/in Dendritic Cells, International PublicationsTargeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirushTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes
/in Dendritic Cells, International PublicationsChanges in peripheral blood level of regulatory T cells in patients with malignant melanoma during treatment with dendritic cell vaccination and low-dose IL-2
/in Dendritic Cells, International Publications, Malignant MelanomaExosome-loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with glioma
/in Dendritic Cells, Exosome, Glioblastoma, International PublicationsPhase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma
/in Dendritic Cells, International Publications, Malignant MelanomaIL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells
/in Dendritic Cells, International Publications, Newcastle Disease VirusHeat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells
/in Dendritic Cells, Hyperthermia, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer